Pharmacoeconomic evaluation is an important tool for drug access and pricing decisions. The results of pharmacoeconomic evaluation carried out under different perspectives are different due to different costs and health outcomes they cover. However, the research perspective that should be adopted for the pharmacoeconomic evaluation to support the adjustment decision of the national reimbursement drug list in China (except Hong Kong, Macao and Taiwan) has not been clearly defined. Based on the submission guidelines of typical countries and regions, this paper analyzed the characteristics and applicable scenarios of different perspectives, and suggested that in China (except Hong Kong, Macao and Taiwan), started from the positioning of basic medical insurance system, the baseline analysis should be conducted from the perspective of basic medical insurance payers, and supplementary analysis should be conducted from other appropriate perspectives. Besides, the costs and health outcomes that should be included in the assessment under the corresponding perspective need to be specified in the submission guidelines.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |